Mirzaten Oro Tab (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten Oro Tab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirzaten Oro Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and related conditions, acting on central neurotransmitter pathways to improve mood.

Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adults. Bipolar depressive episodes (adjunct): used as an add‑on therapy to manage depressive phases. Treatment‑resistant depression (adjunct): considered when first‑line agents have not achieved adequate response.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe leukopenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal ideation or worsening depression - Serotonin syndrome when combined with other serotonergic agents - Hepatotoxicity (rare)

Before initiating therapy, clinicians should consider several safety aspects.

Assess psychiatric history: monitor for worsening depression or suicidal thoughts. Evaluate hepatic function: dose adjustment may be required in severe impairment. Caution in elderly: increased risk of sedation, falls, and anticholinergic effects. Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Anticholinergic drugs: additive dry‑mouth and constipation effects.